blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2877468

EP2877468 - COMPOUNDS AND METHODS FOR TREATING HIV [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.06.2018
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  21.07.2017
FormerGrant of patent is intended
Status updated on  29.03.2017
FormerExamination is in progress
Status updated on  12.12.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
ViiV Healthcare UK Limited
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[2017/17]
Former [2015/23]For all designated states
VIIV Healthcare UK Limited
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Inventor(s)01 / DE LA ROSA, Martha Alicia
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
02 / JOHNS, Brian, Alvin
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
03 / KAZMIERSKI, Wieslaw, Mieczyslaw
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
04 / SAMANO, Vicente
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
05 / SUWANDI, Lita
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
06 / TEMELKOFF, David
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
07 / VELTHUISEN, Emile
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
08 / WEATHERHEAD, Jason, Gordon
c/o GlaxoSmithKline
Global Patents
Five Moore Drive
Research Triangle Park, North Carolina 27709 / US
 [2015/23]
Representative(s)Gladwin, Amanda Rachel, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[2015/23]
Application number, filing date13744796.710.07.2013
[2017/34]
WO2013IB01501
Priority number, dateUS201261670800P12.07.2012         Original published format: US 201261670800 P
US201261671787P15.07.2012         Original published format: US 201261671787 P
US201361755047P22.01.2013         Original published format: US 201361755047 P
US201361764716P14.02.2013         Original published format: US 201361764716 P
[2015/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014009794
Date:16.01.2014
Language:EN
[2014/03]
Type: A1 Application with search report 
No.:EP2877468
Date:03.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 16.01.2014 takes the place of the publication of the European patent application.
[2015/23]
Type: B1 Patent specification 
No.:EP2877468
Date:23.08.2017
Language:EN
[2017/34]
Search report(s)International search report - published on:EP16.01.2014
ClassificationIPC:C07D471/04, C07D471/08, C07D471/14, C07D491/10, A61K31/437, A61P31/18
[2015/23]
CPC:
C07D471/14 (EP,US); A61P31/14 (EP); A61P31/18 (EP);
C07D471/04 (EP,US); C07D471/08 (EP,US); C07D491/10 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/23]
Extension statesBA21.01.2015
ME21.01.2015
TitleGerman:VERBINDUNGEN UND VERFAHREN ZUR BEHANDLUNG VON HIV[2015/23]
English:COMPOUNDS AND METHODS FOR TREATING HIV[2015/23]
French:COMPOSÉS ET PROCÉDÉS DE TRAITEMENT DU VIH[2015/23]
Entry into regional phase21.01.2015National basic fee paid 
21.01.2015Designation fee(s) paid 
21.01.2015Examination fee paid 
Examination procedure21.01.2015Amendment by applicant (claims and/or description)
21.01.2015Examination requested  [2015/23]
11.02.2016Despatch of a communication from the examining division (Time limit: M04)
03.06.2016Reply to a communication from the examining division
01.12.2016Despatch of a communication from the examining division (Time limit: M04)
08.03.2017Reply to a communication from the examining division
30.03.2017Communication of intention to grant the patent
29.06.2017Fee for grant paid
29.06.2017Fee for publishing/printing paid
29.06.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  11.02.2016
Opposition(s)24.05.2018No opposition filed within time limit [2018/31]
Fees paidRenewal fee
09.07.2015Renewal fee patent year 03
11.07.2016Renewal fee patent year 04
10.07.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.07.2013
AL23.08.2017
AT23.08.2017
CY23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
MC23.08.2017
MK23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
TR23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
[2020/34]
Former [2020/31]HU10.07.2013
AT23.08.2017
CY23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
MC23.08.2017
MK23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
TR23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2020/28]HU10.07.2013
AT23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
MC23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
TR23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2020/16]AT23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
MC23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
TR23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2019/15]AT23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
MC23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/40]AT23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SI23.08.2017
SK23.08.2017
SM23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/25]AT23.08.2017
CZ23.08.2017
DK23.08.2017
EE23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
PL23.08.2017
RO23.08.2017
RS23.08.2017
SK23.08.2017
SM23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/21]AT23.08.2017
CZ23.08.2017
DK23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
PL23.08.2017
RS23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/12]AT23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
LV23.08.2017
PL23.08.2017
RS23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/11]AT23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
PL23.08.2017
RS23.08.2017
BG23.11.2017
NO23.11.2017
GR24.11.2017
IS23.12.2017
Former [2018/10]AT23.08.2017
FI23.08.2017
HR23.08.2017
LT23.08.2017
RS23.08.2017
NO23.11.2017
Former [2018/08]FI23.08.2017
LT23.08.2017
NO23.11.2017
Former [2018/07]LT23.08.2017
NO23.11.2017
Cited inInternational search[A]WO2012019003  (SQUIBB BRISTOL MYERS CO [US], et al) [A] 1-17 * page 1, line 4 - line 8 * * claims 1, 8 *;
 [AP]WO2013012649  (GLAXOSMITHKLINE LLC [US], et al) [AP] 1-17 * paragraph [0002] * * table 1; compounds 1-146 * * claims 1, 57 *;
 [AP]WO2013073875  (KOREA RES INST CHEM TECH [KR]) [AP] 1-17 * the whole document *
by applicantGB427857
 WO02074769
 US4107288
 US5145684
    - Fieser and Fieser's Reagents for Organic Synthesis, JOHN WILEY AND SONS, (1991), vol. 1-15
    - Rodd's Chemistry of Carbon Compounds, ELSEVIER SCIENCE PUBLISHERS, (1989), vol. 1-5
    - Organic Reactions, JOHN WILEY AND SONS, (1991), vol. 1-40
    - March's Advanced Organic Chemistry, JOHN WILEY AND SONS
    - Remington's Pharmaceutical Sciences, 17th ed.,, MACK PUBLISHING COMPANY, (1985), page 1418
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY
    - HAZEN ET AL., "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV", ANTIMICROB. AGENTS CHEMOTHER, (2007), vol. 51, pages 3147 - 3154
    - PAUWELS ET AL., "Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus", J. OF VIROLOGICAL METHODS, (1987), vol. 16, doi:doi:10.1016/0166-0934(87)90002-4, pages 171 - 185, XP023695757

DOI:   http://dx.doi.org/10.1016/0166-0934(87)90002-4
 WO2003US39644
 WO2003US39975
 WO2003US39619
 WO2003US39618
 WO2003US39740
 WO2003US39732
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.